Vaccinex Stock Net Income
| VCNX Stock | USD 1.37 0.21 18.10% |
As of the 31st of January, Vaccinex has the Semi Deviation of 12.04, risk adjusted performance of 0.0853, and Coefficient Of Variation of 958.75. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vaccinex, as well as the relationship between them.
Vaccinex's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vaccinex's valuation are provided below:Vaccinex does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Vaccinex |
Vaccinex 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vaccinex's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vaccinex.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Vaccinex on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Vaccinex or generate 0.0% return on investment in Vaccinex over 90 days. Vaccinex is related to or competes with Medigene, Chia Tai, and Biomind Labs. Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through... More
Vaccinex Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vaccinex's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vaccinex upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 17.54 | |||
| Information Ratio | 0.1006 | |||
| Maximum Drawdown | 101.27 | |||
| Value At Risk | (25.37) | |||
| Potential Upside | 32.35 |
Vaccinex Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaccinex's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vaccinex's standard deviation. In reality, there are many statistical measures that can use Vaccinex historical prices to predict the future Vaccinex's volatility.| Risk Adjusted Performance | 0.0853 | |||
| Jensen Alpha | 1.79 | |||
| Total Risk Alpha | 0.5409 | |||
| Sortino Ratio | 0.0939 | |||
| Treynor Ratio | (0.96) |
Vaccinex January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0853 | |||
| Market Risk Adjusted Performance | (0.95) | |||
| Mean Deviation | 9.85 | |||
| Semi Deviation | 12.04 | |||
| Downside Deviation | 17.54 | |||
| Coefficient Of Variation | 958.75 | |||
| Standard Deviation | 16.38 | |||
| Variance | 268.22 | |||
| Information Ratio | 0.1006 | |||
| Jensen Alpha | 1.79 | |||
| Total Risk Alpha | 0.5409 | |||
| Sortino Ratio | 0.0939 | |||
| Treynor Ratio | (0.96) | |||
| Maximum Drawdown | 101.27 | |||
| Value At Risk | (25.37) | |||
| Potential Upside | 32.35 | |||
| Downside Variance | 307.71 | |||
| Semi Variance | 145.01 | |||
| Expected Short fall | (12.82) | |||
| Skewness | 0.7562 | |||
| Kurtosis | 3.76 |
Vaccinex Backtested Returns
Vaccinex is out of control given 3 months investment horizon. Vaccinex owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.18, which indicates the firm had a 0.18 % return per unit of risk over the last 3 months. We were able to interpolate thirty different technical indicators, which can help you to evaluate if expected returns of 2.96% are justified by taking the suggested risk. Use Vaccinex Risk Adjusted Performance of 0.0853, semi deviation of 12.04, and Coefficient Of Variation of 958.75 to evaluate company specific risk that cannot be diversified away. Vaccinex holds a performance score of 14 on a scale of zero to a hundred. The entity has a beta of -1.77, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Vaccinex are expected to decrease by larger amounts. On the other hand, during market turmoil, Vaccinex is expected to outperform it. Use Vaccinex rate of daily change, relative strength index, as well as the relationship between the semi variance and sortino ratio , to analyze future returns on Vaccinex.
Auto-correlation | 0.43 |
Average predictability
Vaccinex has average predictability. Overlapping area represents the amount of predictability between Vaccinex time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vaccinex price movement. The serial correlation of 0.43 indicates that just about 43.0% of current Vaccinex price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.43 | |
| Spearman Rank Test | 0.27 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Vaccinex reported net income of (20.25 Million). This is 105.93% lower than that of the Biotechnology sector and 128.91% lower than that of the Health Care industry. The net income for all United States stocks is 103.55% higher than that of the company.
Vaccinex Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaccinex's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Vaccinex could also be used in its relative valuation, which is a method of valuing Vaccinex by comparing valuation metrics of similar companies.Vaccinex is currently under evaluation in net income category among its peers.
Vaccinex Fundamentals
| Return On Equity | -7.59 | |||
| Return On Asset | -4.96 | |||
| Current Valuation | 1.59 M | |||
| Shares Outstanding | 2.68 M | |||
| Shares Owned By Insiders | 11.50 % | |||
| Shares Owned By Institutions | 51.30 % | |||
| Number Of Shares Shorted | 62.11 K | |||
| Price To Book | 7.34 X | |||
| Price To Sales | 4.34 X | |||
| Revenue | 570 K | |||
| Gross Profit | (13.7 M) | |||
| EBITDA | (19.75 M) | |||
| Net Income | (20.25 M) | |||
| Cash And Equivalents | 11.4 M | |||
| Cash Per Share | 0.27 X | |||
| Total Debt | 247 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 8.22 X | |||
| Book Value Per Share | (2.59) X | |||
| Cash Flow From Operations | (17.23 M) | |||
| Short Ratio | 0.60 X | |||
| Earnings Per Share | 7.42 X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 37 | |||
| Beta | 0.99 | |||
| Market Capitalization | 2.86 M | |||
| Total Asset | 3.63 M | |||
| Retained Earnings | (339.93 M) | |||
| Working Capital | (2.57 M) | |||
| Net Asset | 3.63 M |
About Vaccinex Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaccinex's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaccinex using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaccinex based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaccinex Pink Sheet Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.